Washington State Hikes Cigarette Tax

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 1
Volume 11
Issue 1

OLYMPIA, Washington-The overwhelming approval of a significant tax increase on cigarettes by the residents of Washington State has raised hopes among public health groups that other states will follow suit. By a margin of 65% to 35%,

OLYMPIA, Washington—The overwhelming approval of a significant tax increase on cigarettes by the residents of Washington State has raised hopes among public health groups that other states will follow suit. By a margin of 65% to 35%, Washington voters approved a state ballot initiative that raised the tax on cigarettes by 60 cents to $1.42 a pack. Washington’s excise tax on cigarettes is now the nation’s highest, followed by New York state at $1.11 a pack.

Articles in this issue
ODAC Sends Mixed Message on New Gliadel Wafer Indication
ONCC Certification Test Results Are Announced
Rituximab Ups Survival in Aggressive and Indolent NHL
Topotecan Used in Aggressive Front-Line Therapy for SCLC
Depsipeptide Shows Activity in T-Cell Lymphoma
FDG-PET Useful in Newly Diagnosed and Recurrent NSCLC
Adjuvant Anastrozole Superior to Tamoxifen in Huge ATAC Breast Cancer Trial
ODAC Backs Adding HER-2 DNA Test to Herceptin Package Insert
FDA and VA Plan Joint AIDS Study
Breast Conservation Increases With On-Site Radiation Unit
Washington State Hikes Cigarette Tax
Moffitt’s Diet Guidelines for Immunocompromised Patients
AMA Approves New CPT Code for Serum HER-2 Test
NCI Formalizes Role of Advocates
Better Prognosis for Outer Quadrant Breast Cancers
Recent Videos
6 experts are featured in this series.
6 experts are featured in this series.
Related Content
Data from the MATTERHORN trial show a trend towards improved overall survival with the durvalumab combination in gastric and GEJ cancers.

Durvalumab Combo Meaningfully Improves EFS in Advanced Gastric/GEJ Cancer

Russ Conroy
March 7th 2025
Article

Data from the MATTERHORN trial show a trend towards improved overall survival with the durvalumab combination in gastric and GEJ cancers.

Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Stephanie A. Berg, DO
March 7th 2025
Podcast

A brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.

EC Approves Nivolumab/Ipilimumab in Frontline Unresectable HCC

EC Approves Nivolumab/Ipilimumab in Frontline Unresectable HCC

Tim Cortese
March 7th 2025
Article

The CheckMate 9DW trial found that nivolumab and ipilimumab elicited a median OS of 23.7 months compared with 20.6 months from lenvatinib or sorafenib.

Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;David Morris, MD, MS;Tanya B. Dorff, MD;Mark T. Fleming, MD
March 5th 2025
Podcast

A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.

nenetus-stock.adobe.com

Celebrating Women in Oncology Through Their Impactful Research and Insights

Ariana Pelosci
March 7th 2025
Article

For International Women's Day, CancerNetwork highlights impactful oncology research on topics from rising health care costs to innovative treatments.

Patients with driver gene–negative non–small cell lung cancer who received immunotherapy beyond progression experienced better survival outcomes.

Continuous Second-Line Immunotherapy May Benefit Pretreated Lung Cancer

Roman Fabbricatore
March 6th 2025
Article

Patients with driver gene–negative non–small cell lung cancer who received immunotherapy beyond progression experienced better survival outcomes.